Liver transplant success rate
Liver transplant survival rates are generally strong. The 1-year survival rate is around 85-90%, and the 5-year survival rate is approximately 70-75% for most patients. Living donor transplants tend to have slightly better outcomes than deceased donor transplants. Results vary based on the underlying disease, patient age, and center volume.
Searching sources...
Reading File
Searching the Web
liver transplant success rate survival statistics 2024 2025
Searching PubMed
"liver transplantation"[MeSH Terms] AND "survival rate"[MeSH Terms]
Finding Sources
Reading File
Reading File
Reading File
Here is a thorough breakdown of liver transplant success rates, drawing from surgical textbooks, recent registry data, and current literature:
Liver Transplant Success Rates
Overall Survival Rates (Adults)
| Timepoint | Survival Rate |
|---|---|
| 1-year | ~85-90% |
| 5-year | ~74-75% |
| 10-year | ~55-60% |
These figures come from large registry data. The American Liver Foundation cites an 89% 1-year survival and 75% 5-year survival based on recent registry reports. In 2024, 11,458 liver transplants were performed in the US (10,854 from deceased donors, 604 from living donors).
Survival by Underlying Disease (5-year OS)
| Indication | 5-Year Survival |
|---|---|
| Primary sclerosing cholangitis (PSC) | ~85-86% |
| Hepatitis B (HBV) | ~83% |
| Hepatitis C (HCV) | ~74-75% |
| Alcoholic cirrhosis | ~70-75% |
| HCC (within Milan criteria) | ~73% |
| HCC (outside Milan criteria) | ~53% |
| Metabolic dysfunction-associated steatohepatitis (MASH) | Comparable to other cirrhosis indications |
For PSC specifically, textbook data reports 5-year actuarial survival and graft function of 85% and 72% respectively (Maingot's Abdominal Operations). A 2024 meta-analysis in Hepatology (Ciria et al.) showed 5-year OS rates for transplant oncology indications (e.g., neuroendocrine tumors: 63.2%; perihilar cholangiocarcinoma: 72.5%; colorectal liver metastases: 50.9%) remain above the minimum 50% benchmark when strict selection criteria are applied.
Pediatric Outcomes
Pediatric liver transplants have some of the best outcomes of any transplant type:
- 1-year survival rate: ~90%
- Most common indication: biliary atresia
- (Schwartz's Principles of Surgery, 11th ed.)
Historical Context
Early liver transplant survival (1967-late 1970s) was dismal - only 20% of recipients survived beyond 5 years. The introduction of cyclosporine (1978) and later tacrolimus (1990s) dramatically improved outcomes. Today's ~90% 1-year survival reflects decades of improvements in immunosuppression, cold organ preservation, and surgical technique - (Schwartz's Principles of Surgery, 11th ed.)
Key Factors Affecting Success
Factors that improve outcomes:
- Living donor transplants (slightly better graft quality)
- Lower MELD score at transplant (though a minimum MELD of 18 is needed to show a survival benefit over remaining on the waitlist)
- Younger recipient age
- High-volume transplant centers
Factors that worsen outcomes:
- Sarcopenia (muscle wasting) - a 2025 meta-analysis (PMID 39876624) confirmed sarcopenia is a significant predictor of post-transplant mortality in cirrhosis
- MELD score ≥ 30 at the time of transplant
- Obesity (Class III+)
- Donor risk index (older, marginal donors)
- Disease recurrence (HCV historically; now largely eliminated with direct-acting antivirals)
Graft Survival vs. Patient Survival
These are distinct metrics:
- Patient survival - whether the recipient is alive
- Graft survival - whether the transplanted liver is still functioning
Graft survival is slightly lower than patient survival at each time point, because some patients survive after re-transplantation if the first graft fails.
Long-term Perspective
Recipients have been documented to live normal lives for 30+ years after transplantation. The transplanted liver does not age at the same rate as the rest of the body, and many long-term complications relate to chronic immunosuppression (infection, malignancy, metabolic syndrome) rather than graft failure itself.
This is a shared conversation. Sign in to Orris to start your own chat.